Cosmetic medical devices and their FDA regulation

Archives of Dermatology

Volumn 142, Issue 2, 2006, Pages 225-228

  Newburger, Amy E ^a  

^a Dermatol Consultants of Westchester   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYAPATITE; POLYLACTIC ACID; SILICONE;

DEVICE; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG SAFETY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LASER; MEDICAL PRACTICE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SAFETY;

COSMETIC TECHNIQUES; DEVICE APPROVAL; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33244470688     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.142.2.225     Document Type: Editorial

References (18)

1. Saladi RN, Cohen SR, Phelps RG, Persaud AN, Rudikoff D. Diltiazem induces severe photodistributed hyperpigmentation: case series, histoimmunopathology, management, and review of the literature. Arch Dermatol. 2006;142:206-210.
2. Deng A, Harvey V, Sina B, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor α inhibitors. Arch Dermatol. 2006;142:198-202.
3. Vecchietti G, Kerl K, Prins C, Kaya G, Saurat J-H, French LE. Severe eczematous skin reaction after high-dose intravenous immunoglobulin infusion: report of 4 cases and review of the literature. Arch Dermatol. 2006;142:213-217.
4. Winfield H, Lain E, Horn T, Hoskyn J. Eosinophilic cellulitislike reaction to subcutaneous etanercept injection. Arch Dermatol. 2006;142:218-220.
5. The Medical Device Amendments of 1976, Pub L No. 94-295, Sec 3 (codified as amended at 21 USC § 321 (a)(1)(A)(h)(2005)).
6. US Food and Drug Administration Web site. Is the Product a Medical Device? Available at: www.fda.gov/cdrh/devadvice/312.html. Accessed December 12, 2005.
7. Swann J. History of the FDA. In: Kurian G, ed. A Historical Guide to the US Government. New York, NY: Oxford University Press; 1998.
8. Advanced Medical Technology Association Web site. Inside FDA: a history of the regulatory process. April 2004. Available at: www.advamed.org/newsroom/ regulatory/fdahistory.pdf. Accessed December 12, 2005.
9. The Medical Device Amendments of 1976, Pub L No. 94-295, Sec 2 (codified as amended at 21 USC § 360c(2005)).
10. Food, Drug & Cosmetic Act, 21 USC §§360c(a)(1)(B), 360(k)(2005).
11. Food, Drug & Cosmetic Act, 21 USC §360c(a)(1)(C)(ii)(1)(2005).
12. Food and Drug Administration Modernization Act of 1997, Pub L No. 105-115, Sec 513(a)(codified as amended at 21 USC §360c(a)(3)(2005).
13. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151-185.
14. US Food and Drug Administration Web site. FDA Office of Device Evaluation annual report, fiscal year 2004. Available at: www.fda.gov/cdrh/annual/FY2004/ ode/2004.pdf. Accessed December 12, 2005.
15. How to stop the clock on aging [transcript]. The Oprah Winfrey Show, September 18, 2003. Available at: www.oprah.com. Accessed December 12, 2005.
16. US Food and Drug Adminstration Web site. Manufacturer and user facility device experience (MAUDE) database. Available at: www.fda.gov/cdrh/maude.html. Accessed December 7, 2005.
17. US Food and Drug Adminsitration Web site. "Off-label" and investigational use of marketed drugs, biologics, and medical devices. Available at: www.fda.gov/oc/ohrt/irbs/offlabel.html. Accessed December 7, 2005.
18. Beljaards RC, de Roos KP, Bruins FG. NewFill for skin augmentation: a new filler or failure? Dermatol Surg. 2005;31:772-776.